Musella Foundation Brain Tumor Awareness Webinar Series presented on 5/16/21 Session 2: By Dr Christopher Chitambar

Michael Barish, Ph.D., is chair of the Department of Neurosciences at Beckman Research Institute of City of Hope. Learn more about Dr. Barish at http://www.cityofhope.org/people/barish-michael. Find out more about the Department of Neurosciences at http://www.cityofhope.org/neurosciences ################ CONNECT WITH US WEBSITE: http://www.cityofhope.org FACEBOOK: http://www.facebook.com/cityofhope TWITTER: http://www.twitter.com/cityofhope YOUTUBE: http://www.youtube.com/cityofhopeonline FLICKR: http://www.flickr.com/cityofhope BLOG: http://breakthroughs.cityofhope.org and MORE: http://www.cityofhope.org/getsocial ################ ABOUT CITY OF HOPE City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the nation. City of Hope's main hospital is located in Duarte, Calif., just northeast of Los Angeles, with clinics throughout southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. For more information, visit http://www.cityofhope.org.

Dr. Theodore Schwartz, David and Ursel Barnes Professor in Minimally Invasive Surgery and co-director of surgical neuro-oncology at the Weill Cornell Medicine Brain and Spine Center, recently became the first surgeon at NewYork-Presbyterian Weill Cornell to use Gleolan, dubbed “the pink drink,” during surgery to remove a high-grade glioma. Find out more at https://weillcornellbrainandspine.org

The physician founders of GT Medical Technologies explain how GammaTile Therapy was developed and how the therapy treats recurrent brain tumors. MKT025A

In clinical trials, 97% of patients receiving a new glioblastoma vaccine did not experience tumor progression in the six months following treatment. Learn more about the immunotherapy under development.

For more information on glioblastoma, please visit http://cle.clinic/3eu0iNs Cleveland Clinic researchers use artificial intelligence to predict drugs that could target glioblastoma cells in men and women. ▶Share this video with others: https://youtu.be/6u0YDQeOYUs ▶Subscribe to learn more about Cleveland Clinic: https://www.youtube.com/user/ClevelandClinic?sub_confirmation=1

AutoLITT utilizes precise laser technology to accurately target, heat and destroy brain tumors. Gene Barnett, MD, Director of the Burkhardt Brain Tumor Center at Cleveland Clinic, along with one of his AutoLITT patients, discuss the minimally invasive brain tumor treatment and overall experience. Cleveland Clinic has extensive surgical experience with this leading-edge procedure, offering new hope for patients with inoperable brain tumors.

For more information on Cleveland Clinic’s Brain Tumor Center, please visit https://cle.clinic/3gAe53d Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center is a nationally recognized leader in the diagnosis and treatment of primary and metastatic spine, nerve and brain tumors and their effects on the nervous system. Annually, the center’s physicians record approximately 8,000 patient visits and perform more than 900 surgeries, and offers multidisciplinary physicians and nurses who work closely together to provide the best care for patients. ▶Share this video with others: https://youtu.be/pscCUzgWk1M ▶Subscribe to learn more about Cleveland Clinic: https://www.youtube.com/user/ClevelandClinic?sub_confirmation=1

Dr. Gene Barnett - Bio Video